Gene expression in circulating tumor cells (CTC) and plasma androgen receptor (AR) gene copy number (CN) for castration-resistant prostate cancer (CRPC) patients (pts) treated with cabazitaxel.

Giorgia Gurioli,Vincenza Conteduca,Umberto Basso,Giuseppe Fornarini,Alessandra Mosca,Maurizio Nicodemo,Giuseppe Luigi Banna,Cristian Lolli,Giuseppe Schepisi,Stefania Gargiulo,Amelia Altavilla,Sara Testoni,Emanuela Scarpi,Ugo De Giorgi

Gene expression in circulating tumor cells (CTC) and plasma androgen receptor (AR) gene copy number (CN) for castration-resistant prostate cancer (CRPC) patients (pts) treated with cabazitaxel.

2020

Giorgia Gurioli
Vincenza Conteduca
Umberto Basso
Giuseppe Fornarini
Alessandra Mosca
Maurizio Nicodemo
Giuseppe Luigi Banna
Cristian Lolli
Giuseppe Schepisi
Stefania Gargiulo
Amelia Altavilla
Sara Testoni
Emanuela Scarpi
Ugo De Giorgi

154Background: Cabazitaxel demonstrated overall survival (OS) benefit for the treatment of CRPC progressing after docetaxel. CTC profiling could help to establish novel predictive biomarkers. In th...

Keywords:

Prostate cancer
Cancer research
Castration
Cabazitaxel
Androgen receptor
Gene expression
Pathology
Circulating tumor cell
Copy-number variation
Medicine
castration resistant
Docetaxel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations